schliessen

Filtern

 

Bibliotheken

Valsartan treatment of hypertension—does VALUE add value?

The primary endpoint in LIFE (non-fatal and fatal cardiovascular disease) occurred in 508 patients on losartan (23.8 per 1000 patient-years) and in 588 patients on atenolol (27.9 per 1000 patient-years, p=0.02). 232 and 309 patients, respectively, had a fatal or non-fatal stroke (p=0.001); and 198 a... Full description

Journal Title: The Lancet (British edition) 2004-06-19, Vol.363 (9426), p.2010-2011
Main Author: Lindholm, Lars H
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/15207946
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_66654151
title: Valsartan treatment of hypertension—does VALUE add value?
format: Article
creator:
  • Lindholm, Lars H
subjects:
  • Abridged Index Medicus
  • Aged
  • Amlodipine - therapeutic use
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents - therapeutic use
  • Benzimidazoles - therapeutic use
  • Blood pressure
  • Blood Pressure - drug effects
  • Calcium Channel Blockers - therapeutic use
  • Cardiovascular disease
  • Diabetes
  • Drug therapy
  • Endpoint Determination
  • Heart attacks
  • Humans
  • Hypertension
  • Hypertension - drug therapy
  • Hypertension - physiopathology
  • Losartan - therapeutic use
  • Medical research
  • Patients
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Side effects
  • Stroke
  • Tetrazoles - therapeutic use
  • Valine - analogs & derivatives
  • Valine - therapeutic use
  • Valsartan
ispartof: The Lancet (British edition), 2004-06-19, Vol.363 (9426), p.2010-2011
description: The primary endpoint in LIFE (non-fatal and fatal cardiovascular disease) occurred in 508 patients on losartan (23.8 per 1000 patient-years) and in 588 patients on atenolol (27.9 per 1000 patient-years, p=0.02). 232 and 309 patients, respectively, had a fatal or non-fatal stroke (p=0.001); and 198 and 188 patients, respectively, had myocardial infarction (non-fatal and fatal; not statistically significant). New-onset diabetes mellitus was less frequent in the losartan than in the atenolol group (6.0% vs 8.0%, p
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.0324266
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_66654151
sourceformatXML
sourcesystemPC
sourcerecordid657591681
originalsourceidFETCH-LOGICAL-c355t-397e75cf5d0350978c12febd7f0534ac624b389f61c8e9101b1406e30fc434833
addsrcrecordideNqFkc1Kw0AUhQdRbK0-ghIURBfRO5m_DC5ESv2Bggt_cDdMJzeY0iZ1JhG68yF8Qp_E1BYFQVzdzXfOvfccQnYpnFCg8vQOKIdYKiaPgB9TyVMeJ2ukS7niseDqaZ10v5EO2QphDABcgtgkHSoSUJrLLjl7tJNgfW3LqPZo6ymWdVTl0fN8hr7GMhRV-fH2nlUYoseL4cMgslkWvdpJg-fbZCNv1bizmj3ycDm471_Hw9urm_7FMHZMiDpmWqESLhcZMAFapY4mOY4ylYNg3DqZ8BFLdS6pS1G3z43asyUyyB1nPGWsRw6XvjNfvTQYajMtgsPJxJZYNcFIKQWngrbgwS9wXDW-bG8zCUitEwpsQe3_RVGdap0qSFpILCHnqxA85mbmi6n1c0PBLAowXwWYRboGuPkqwCx0eyvzZjTF7Ee1SrwFzpcAtom9FuhNcAWWDrPCo6tNVhX_rPgEuLqSwg
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid198998702
display
typearticle
titleValsartan treatment of hypertension—does VALUE add value?
sourceAlma/SFX Local Collection
creatorLindholm, Lars H
creatorcontribLindholm, Lars H
descriptionThe primary endpoint in LIFE (non-fatal and fatal cardiovascular disease) occurred in 508 patients on losartan (23.8 per 1000 patient-years) and in 588 patients on atenolol (27.9 per 1000 patient-years, p=0.02). 232 and 309 patients, respectively, had a fatal or non-fatal stroke (p=0.001); and 198 and 188 patients, respectively, had myocardial infarction (non-fatal and fatal; not statistically significant). New-onset diabetes mellitus was less frequent in the losartan than in the atenolol group (6.0% vs 8.0%, p<0.001).3 It cannot be determined whether the lower frequency of cardiovascular events in the losartan-treated patients reflects only an effect of this drug or whether a weak cardiovascular effect of atenolol contributed.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(04)16484-2
3PMID: 15207946
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subjectAbridged Index Medicus ; Aged ; Amlodipine - therapeutic use ; Angiotensin II Type 1 Receptor Blockers ; Antihypertensive Agents - therapeutic use ; Benzimidazoles - therapeutic use ; Blood pressure ; Blood Pressure - drug effects ; Calcium Channel Blockers - therapeutic use ; Cardiovascular disease ; Diabetes ; Drug therapy ; Endpoint Determination ; Heart attacks ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - physiopathology ; Losartan - therapeutic use ; Medical research ; Patients ; Randomized Controlled Trials as Topic ; Risk Factors ; Side effects ; Stroke ; Tetrazoles - therapeutic use ; Valine - analogs & derivatives ; Valine - therapeutic use ; Valsartan
ispartofThe Lancet (British edition), 2004-06-19, Vol.363 (9426), p.2010-2011
rights
02004 Elsevier Ltd
1Copyright Lancet Ltd. Jun 19, 2004
2Copyright Elsevier Limited Jun 19, 2004
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15207946$$D View this record in MEDLINE/PubMed
search
creatorcontribLindholm, Lars H
title
0Valsartan treatment of hypertension—does VALUE add value?
1The Lancet (British edition)
addtitleLancet
descriptionThe primary endpoint in LIFE (non-fatal and fatal cardiovascular disease) occurred in 508 patients on losartan (23.8 per 1000 patient-years) and in 588 patients on atenolol (27.9 per 1000 patient-years, p=0.02). 232 and 309 patients, respectively, had a fatal or non-fatal stroke (p=0.001); and 198 and 188 patients, respectively, had myocardial infarction (non-fatal and fatal; not statistically significant). New-onset diabetes mellitus was less frequent in the losartan than in the atenolol group (6.0% vs 8.0%, p<0.001).3 It cannot be determined whether the lower frequency of cardiovascular events in the losartan-treated patients reflects only an effect of this drug or whether a weak cardiovascular effect of atenolol contributed.
subject
0Abridged Index Medicus
1Aged
2Amlodipine - therapeutic use
3Angiotensin II Type 1 Receptor Blockers
4Antihypertensive Agents - therapeutic use
5Benzimidazoles - therapeutic use
6Blood pressure
7Blood Pressure - drug effects
8Calcium Channel Blockers - therapeutic use
9Cardiovascular disease
10Diabetes
11Drug therapy
12Endpoint Determination
13Heart attacks
14Humans
15Hypertension
16Hypertension - drug therapy
17Hypertension - physiopathology
18Losartan - therapeutic use
19Medical research
20Patients
21Randomized Controlled Trials as Topic
22Risk Factors
23Side effects
24Stroke
25Tetrazoles - therapeutic use
26Valine - analogs & derivatives
27Valine - therapeutic use
28Valsartan
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2004
recordtypearticle
recordideNqFkc1Kw0AUhQdRbK0-ghIURBfRO5m_DC5ESv2Bggt_cDdMJzeY0iZ1JhG68yF8Qp_E1BYFQVzdzXfOvfccQnYpnFCg8vQOKIdYKiaPgB9TyVMeJ2ukS7niseDqaZ10v5EO2QphDABcgtgkHSoSUJrLLjl7tJNgfW3LqPZo6ymWdVTl0fN8hr7GMhRV-fH2nlUYoseL4cMgslkWvdpJg-fbZCNv1bizmj3ycDm471_Hw9urm_7FMHZMiDpmWqESLhcZMAFapY4mOY4ylYNg3DqZ8BFLdS6pS1G3z43asyUyyB1nPGWsRw6XvjNfvTQYajMtgsPJxJZYNcFIKQWngrbgwS9wXDW-bG8zCUitEwpsQe3_RVGdap0qSFpILCHnqxA85mbmi6n1c0PBLAowXwWYRboGuPkqwCx0eyvzZjTF7Ee1SrwFzpcAtom9FuhNcAWWDrPCo6tNVhX_rPgEuLqSwg
startdate20040619
enddate20040619
creatorLindholm, Lars H
general
0Elsevier Ltd
1Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
80TT
90TZ
100U~
113V.
127QL
137QP
147RV
157TK
167U7
177U9
187X7
197XB
2088A
2188C
2288E
2388G
2488I
258AF
268AO
278C1
288C2
298FE
308FH
318FI
328FJ
338FK
348G5
35ABUWG
36AN0
37ASE
38AZQEC
39BBNVY
40BEC
41BENPR
42BHPHI
43C1K
44DWQXO
45FPQ
46FYUFA
47GHDGH
48GNUQQ
49GUQSH
50H94
51HCIFZ
52K6X
53K9-
54K9.
55KB0
56KB~
57LK8
58M0R
59M0S
60M0T
61M1P
62M2M
63M2O
64M2P
65M7N
66M7P
67MBDVC
68NAPCQ
69PQEST
70PQQKQ
71PQUKI
72Q9U
73S0X
747X8
sort
creationdate20040619
titleValsartan treatment of hypertension—does VALUE add value?
authorLindholm, Lars H
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c355t-397e75cf5d0350978c12febd7f0534ac624b389f61c8e9101b1406e30fc434833
rsrctypearticles
prefilterarticles
languageeng
creationdate2004
topic
0Abridged Index Medicus
1Aged
2Amlodipine - therapeutic use
3Angiotensin II Type 1 Receptor Blockers
4Antihypertensive Agents - therapeutic use
5Benzimidazoles - therapeutic use
6Blood pressure
7Blood Pressure - drug effects
8Calcium Channel Blockers - therapeutic use
9Cardiovascular disease
10Diabetes
11Drug therapy
12Endpoint Determination
13Heart attacks
14Humans
15Hypertension
16Hypertension - drug therapy
17Hypertension - physiopathology
18Losartan - therapeutic use
19Medical research
20Patients
21Randomized Controlled Trials as Topic
22Risk Factors
23Side effects
24Stroke
25Tetrazoles - therapeutic use
26Valine - analogs & derivatives
27Valine - therapeutic use
28Valsartan
toplevel
0peer_reviewed
1online_resources
creatorcontribLindholm, Lars H
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7News PRO
8Pharma and Biotech Premium PRO
9Global News & ABI/Inform Professional
10ProQuest Central (Corporate)
11Bacteriology Abstracts (Microbiology B)
12Calcium & Calcified Tissue Abstracts
13Nursing & Allied Health Database
14Neurosciences Abstracts
15Toxicology Abstracts
16Virology and AIDS Abstracts
17Health & Medical Collection
18ProQuest Central (purchase pre-March 2016)
19Biology Database (Alumni Edition)
20Healthcare Administration Database (Alumni)
21Medical Database (Alumni Edition)
22Psychology Database (Alumni)
23Science Database (Alumni Edition)
24STEM Database
25ProQuest Pharma Collection
26Public Health Database
27Lancet Titles
28ProQuest SciTech Collection
29ProQuest Natural Science Collection
30Hospital Premium Collection
31Hospital Premium Collection (Alumni Edition)
32ProQuest Central (Alumni) (purchase pre-March 2016)
33Research Library (Alumni Edition)
34ProQuest Central (Alumni Edition)
35British Nursing Database
36British Nursing Index
37ProQuest Central Essentials
38Biological Science Collection
39eLibrary
40ProQuest Central
41Natural Science Collection
42Environmental Sciences and Pollution Management
43ProQuest Central Korea
44British Nursing Index (BNI) (1985 to Present)
45Health Research Premium Collection
46Health Research Premium Collection (Alumni)
47ProQuest Central Student
48Research Library Prep
49AIDS and Cancer Research Abstracts
50SciTech Premium Collection
51British Nursing Index
52Consumer Health Database (Alumni Edition)
53ProQuest Health & Medical Complete (Alumni)
54Nursing & Allied Health Database (Alumni Edition)
55ProQuest Newsstand Professional
56ProQuest Biological Science Collection
57Consumer Health Database
58Health & Medical Collection (Alumni Edition)
59Healthcare Administration Database
60Medical Database
61Psychology Database
62Research Library
63Science Database
64Algology Mycology and Protozoology Abstracts (Microbiology C)
65Biological Science Database
66Research Library (Corporate)
67Nursing & Allied Health Premium
68ProQuest One Academic Eastern Edition
69ProQuest One Academic
70ProQuest One Academic UKI Edition
71ProQuest Central Basic
72SIRS Editorial
73MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
auLindholm, Lars H
formatjournal
genrearticle
ristypeJOUR
atitleValsartan treatment of hypertension—does VALUE add value?
jtitleThe Lancet (British edition)
addtitleLancet
date2004-06-19
risdate2004
volume363
issue9426
spage2010
epage2011
pages2010-2011
issn0140-6736
eissn1474-547X
codenLANCAO
abstractThe primary endpoint in LIFE (non-fatal and fatal cardiovascular disease) occurred in 508 patients on losartan (23.8 per 1000 patient-years) and in 588 patients on atenolol (27.9 per 1000 patient-years, p=0.02). 232 and 309 patients, respectively, had a fatal or non-fatal stroke (p=0.001); and 198 and 188 patients, respectively, had myocardial infarction (non-fatal and fatal; not statistically significant). New-onset diabetes mellitus was less frequent in the losartan than in the atenolol group (6.0% vs 8.0%, p<0.001).3 It cannot be determined whether the lower frequency of cardiovascular events in the losartan-treated patients reflects only an effect of this drug or whether a weak cardiovascular effect of atenolol contributed.
copEngland
pubElsevier Ltd
pmid15207946
doi10.1016/S0140-6736(04)16484-2